Cutting-edge diagnostic platforms are emerging to improve cancer detection and patient monitoring. Plus Therapeutics announced plans to relaunch CNSide assay for cerebrospinal fluid analysis to detect central nervous system metastases with immunocytochemistry and FISH techniques, aiming for expanded U.S. availability. Wholomics shared promising metabolomic multi-cancer detection data using nuclear magnetic resonance to identify tumor-associated metabolic signatures, offering sensitivity improvements over DNA-based approaches. These innovations provide enhanced tools for personalized oncology diagnostics and treatment management.